Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carnitine O-palmitoyltransferase 1 (CPT1) is a mitochondrial enzyme crucial for the metabolism of long-chain fatty acids. It catalyzes the transfer of an acyl group from long-chain fatty acyl-CoA to L-carnitine, forming acyl-carnitines such as palmitoylcarnitine. This reaction is essential for transporting fatty acids into mitochondria for β-oxidation and energy production. CPT1 exists in three main isoforms in humans: CPT1A (Liver), CPT1B (Muscle), and CPT1C (Brain). CPT1 activity is tightly regulated, inhibited by malonyl-CoA, which links it directly to control by pathways involved in fatty acid synthesis versus oxidation. Mutations or deficiencies in CPT1 lead to carnitine palmitoyltransferase I deficiency, a rare metabolic disorder characterized by hypoketotic hypoglycemia during fasting or illness.
Catalyzes the transfer of an acyl group from long-chain fatty acyl-CoA to L-carnitine, facilitating transport of fatty acids into the mitochondria for beta-oxidation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carnitine O-palmitoyltransferase 1 (CPT1).